The D-SOLVE Consortium

Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of Hepatitis D

Prof. Dr. Heiner Wedemeyer

The D-SOLVE consortium is funded by the European Union in the Horizon Europe Framework Programme (HORIZON) under grant agreement No 101057917.

Funded by the European Union

Gastroenterology Hepatology Endocrinology

CiiM CENTRE FOR INDIVIDUALISED INFECTION MEDICINE

Hannover Medical School

The pathogen in a nutshell: Hepatitis D virus

D-SOLVE

- Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and death
- Hepatitis D is caused by coinfection of hepatitis B patients with the hepatitis D virus (HDV)
- Large interindividual variability in the course of hepatitis D



→ **protype infection for individualized infectious medicine approach**

BUT orphan disease

- Limited knowledge on disease pathophysiology and host-virus interactions
- No multicenter cohorts of HDV infected patients are available

→ **urgent need to better understand individual factors determining the outcome of infection and to identify subjects benefitting from currently available treatments**

The Aim

D-SOLVE

- Unbiased screening of a large multicenter cohort of well-defined HDV-infected patients
- Mechanistic studies to determine the functional role of distinct molecules
- Identification of specific parameters and prognostic markers

The Approach

- *Key clinical questions on viral control, disease progression and treatment response will be studied across 4 research WPs*
- *Similar methodological approaches will be applied for all clinical questions*



Clinical cohort A: cross-sectional screening cohort of 750 HDV patients. Clinical cohort B: retrospective-prospective group of patients where liver biopsies have been taken 10-20 years ago and which are now available for immunological studies. Clinical cohort C: prospective clinical trial where controlled stopping of bulevirtide is explored.

The Consortium: Partner

D-SOLVE

HZI HELMHOLTZ Centre for Infection Research

Kompetenznetz Hepatitis HepNet Study-House

MHH

CiiM

CISPA HELMHOLTZ CENTER FOR INFORMATION SECURITY

Inserm

FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO

KAROLINSKA Universitetssjukhuset

Karolinska Institutet

INSTITUTUL NAȚIONAL DE BOLI INFECȚIOASE "PROF. DR. MATEI BALȘ"



The Consortium: Expertise

- Several of the leading experts in European HDV research contribute to D-SOLVE
- Clinical centers with an outstanding experience in translational research
- High-level knowledge in performing an unbiased and broad biomarker screening from host genetics to host transcriptome and proteome analysis
- Mechanistic studies will be performed by foremost specialists in human immunology, HDV immunity and viral hepatitis research



The Consortium

D-SOLVE

CISPA
HELMHOLTZ CENTER FOR INFORMATION SECURITY

CiiM

MHH

KAROLINSKA
Universitetssjukhuset

HZI HELMHOLTZ
Centre for Infection Research

Karolinska Institutet

INSTITUTUL NAȚIONAL
DE BOLI INFECȚIOASE
"PROF. DR. MATEI BALȘ"

Inserm

Gastroenterology
Hepatology
Endocrinology

CiiM
CENTRE FOR INDIVIDUALISED INFECTION MEDICINE

FONDAZIONE IRCCS CA' GRANDA
OSPEDALE MAGGIORE POLICLINICO

MHH Hannover Medical School